Study Overview
This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.
Description
This is purpose of this study is to evaluate the safety, tolerability, and effect on Albuminuria of MZE829 in Adults with APOL1 Kidney Disease
Official Title
An Open-Label Phase 2 Study to Evaluate the Safety, Tolerability, and Effect on Albuminuria of MZE829 in Adults with Proteinuric Chronic Kidney Disease and the APOL1 High Risk Genotype
Quick Facts
Study Start:2025-02-05
Study Completion:2026-09
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
| Inclusion Criteria | Exclusion Criteria |
|---|
| |
Contacts and Locations
Study Locations (Sites)
Apogee Clinical Research
Huntsville, Alabama, 35805
United States
Amicis Research Center
Fairfield, California, 94534
United States
Amicis Research Center
Granada Hills, California, 91344
United States
Amicis Research Center
Palmdale, California, 93551
United States
Amicis Research Center
Valencia, California, 91355
United States
Clinical Research of Brandon, LLC
Brandon, Florida, 33511
United States
Florida Kidney Physicians
Fort Lauderdale, Florida, 33316
United States
Florida Kidney Physicians
Jacksonville, Florida, 32250
United States
San Marcus Research Clinic, Inc.
Miami Lakes, Florida, 33014
United States
Florida Kidney Physicians
Riverview, Florida, 33578
United States
Primeway Clinical Research Group
College Park, Georgia, 30349
United States
Research by Design, LLC
Chicago, Illinois, 60643
United States
Aa Mrc Mhs
Flint, Michigan, 48503
United States
St. Clair Nephrology Research
Shelby Township, Michigan, 48315
United States
Prime Health and Wellness
Fayette, Mississippi, 39069
United States
SKY Integrative Medical Center
Ridgeland, Mississippi, 39157
United States
AB Clinical Trials
Las Vegas, Nevada, 89119
United States
Carolina Kidney Associates, P.A.
Greensboro, North Carolina, 27405
United States
Clinical Renal Associates
Upland, Pennsylvania, 19013
United States
CN Clinical Research, LLC
Spartanburg, South Carolina, 29306
United States
Renal Specialist
Houston, Texas, 77030
United States
Virginia Nephrology Group
Arlington, Virginia, 22205
United States
Collaborators and Investigators
Sponsor: Maze Therapeutics
- Medical Director, STUDY_DIRECTOR, Maze Therapeutics
Study Record Dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Registration Dates
Study Start Date2025-02-05
Study Completion Date2026-09
Study Record Updates
Study Start Date2025-02-05
Study Completion Date2026-09
Terms related to this study
Keywords Provided by Researchers
- APOL1-mediated kidney disease (AMKD)
- APOL1 kidney disease (AKD)
Additional Relevant MeSH Terms
- Proteinuric Kidney Disease